DELRAY BEACH, Fla., March 6, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Chemiluminescence Immunoassay Market is projected to grow from about USD 11.58 billion in 2026 to USD 16.39 billion by 2031, at a CAGR of 7.2%.
Browse through 380 market data tables and 65 figures spread across 400 pages and the in-depth TOC on the "Chemiluminescence immunoassays market - Global Forecast to 2031"
Chemiluminescence Immunoassay Market Size & Forecast:
Chemiluminescence Immunoassay Market Trends & Insights:
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131865271
The CLIA market demonstrates its growth through the increasing global incidence of chronic and infectious diseases, which include cancer, cardiovascular disorders, thyroid diseases, and viral infections that require highly accurate and dependable diagnostic tests. The rising emphasis on early disease detection and preventive healthcare drives CLIA adoption because it provides better testing results through its advanced sensitivity, wide testing range, and capacity to find minute biological indicators. Laboratory operations achieve better performance because technological advancements deliver fully automated, high-throughput analyzers, improved reagent stability, and enhanced multiplex testing capabilities. The market expansion receives additional support through three factors, which include emerging markets building new healthcare facilities, expanding diagnostic laboratory networks, and increasing healthcare spending. The demand for CLIA systems in hospital and reference laboratory settings worldwide continues to grow because of two factors, which include the rising use of biomarker-based testing in personalized medicine and pharmaceutical research and clinical trials, and the strict blood screening standards and the public's increased knowledge of routine health checkups.
By product, the consumables segment is expected to grow at the highest CAGR during the forecast period.
The consumables segment is experiencing strong growth because diagnostic testing needs require constant and high-volume consumption of reagents and other essential materials, which include calibrators and controls, wash solutions, and reaction cuvettes. The need for assay kits and reagent packs in hospitals and reference laboratories has increased because test volumes for infectious diseases, cancer biomarkers, cardiac markers, endocrine disorders, and therapeutic drug monitoring have risen. The market experiences regular revenue generation through consumables because they need to be restocked, which leads to ongoing business growth. Laboratory efficiency improves through enhancements in reagent stability and ready-to-use formulations, extended product shelf life, and enhanced quality controls, which result in less waste and increased user adoption. The global consumption of CLIA reagents and related supplies continues to rise because automated high-throughput CLIA systems need more testing capabilities, and as preventive health screening programs expand, blood safety testing requirements grow.
Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=131865271
By sample type, the saliva segment is expected to grow at the highest CAGR during the forecast period.
The growth of the saliva sample type segment is driven by the increasing demand for non-invasive, patient-friendly diagnostic methods that improve comfort and compliance compared to blood collection. Saliva testing eliminates the requirement for certified phlebotomists while it decreases infection dangers and allows users to gather samples easily at hospitals, their homes, and during public health testing events. The development of better assay sensitivity, together with improved biomarker detection technologies, has made saliva testing more trustworthy for its use in hormone assessment (such as cortisol monitoring), infectious disease testing, and drug detection and evaluation of stress and metabolic functions. The growing use of remote healthcare services, including telemedicine and decentralized testing systems, is driving demand for saliva sample collection methods.
By end user, the saliva segment is expected to grow at the highest CAGR during the forecast period.
The chemiluminescence immunoassay (CLIA) market is growing in the hospital segment because hospitals require efficient testing solutions that deliver precise results to facilitate quick medical decisions, ultimately leading to better patient outcomes. Hospitals require dependable tests to assess cardiac markers, sepsis indicators, cancer biomarkers, hormones, and infectious pathogens because they treat numerous patients with chronic diseases and infectious diseases. The CLIA system enables emergency departments, intensive care units, and inpatient services to start immediate medical treatment through its enhanced sensitivity, extensive test options, and quick result delivery. The implementation of centralized hospital laboratories together with automated diagnostic systems establishes efficient work processes while diminishing manual mistakes and producing uniform test outcomes.
North America dominates the global chemiluminescence immunoassays market in 2025.
The chemiluminescence immunoassay market in North America is growing as hospitals and reference laboratories in the region adopt automated diagnostic technologies, and the region has advanced healthcare systems and spends heavily on healthcare services. The region requires advanced biomarker detection technologies that can identify markers of various chronic and infectious diseases, including cancer and cardiovascular disorders, and endocrine conditions. These tests receive broad usage because strong reimbursement systems, helpful regulatory processes, and regular test approvals enable medical facilities to perform testing outside traditional laboratory settings. The combination of strong research and development funding, major diagnostic companies operating in the market, and ongoing advancements, which include laboratory automation, artificial intelligence development, and the introduction of new testing methods, will lead to laboratory testing process improvements and more accurate diagnostic results.
Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=131865271
Top Companies in Chemiluminescence Immunoassay Market:
The Top Companies in Chemiluminescence Immunoassay Market include F. Hoffmann-La Roche Ltd. (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), DiaSorin S.p.A. (Italy), Tosoh Corporation (Japan), Werfen (Spain), Bio-Rad Laboratories, Inc. (US), Shenzhen Mindray Biomedical Electronics Co., Ltd. (China), Fujirebio (Japan), Autobio Diagnostics Co., Ltd. (China), Artron Laboratories Inc. (Canada), Abnova Corporation (Taiwan), and Elabscience (China).
Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
Related Reports:
Infectious Disease Diagnostics Market - Global Forecast to 2030
Interventional Oncology Market - Global Forecast to 2029
Immunoassay Market - Global Forecast to 2030
Life Science Instrumentation Market - Global Forecast to 2031
Medical Robots Market - Global Forecast to 2029
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
MarketsandMarkets™ SalesPlay is an AI-driven Revenue Intelligence Co-Pilot designed to help revenue teams prioritize the right accounts, identify critical changes early, and surface opportunities ahead of demand, so pipeline builds naturally and deals close with greater consistency.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
Logo: https://mma.prnewswire.com/media/1868219/MarketsandMarkets_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/chemiluminescence-immunoassay-market-worth-16-39-billion-by-2031--marketsandmarkets-302706511.html
Die Panne im E-Voting-System des Kantons Basel-Stadt setzt dem digitalen Abstimmen in der Schweiz vorerst enge Grenzen – aber nicht überall. Nachdem bei der eidgenössischen Volksabstimmung vom 8. März 2026 insgesamt 2048 elektronisch abgegebene Stimmen in Basel-Stadt wegen einer nicht entschlüsselbaren «elektronischen Urne» verloren gingen, stoppt der Stadtkanton seinen Versuchsbetrieb bis Ende 2026. Die Bundeskanzlei spricht von einer schweren Verletzung der politischen Rechte der Betroffenen, sieht derzeit aber keinen Anlass, den gesamtschweizerischen Versuchsbetrieb grundsätzlich infrage zu stellen.
Auslöser des Vorfalls war nach kantonalen Angaben ein Problem im Umgang mit einem USB-Datenträger, der im Auszählprozess eine Rolle spielte. Die Folge: Sämtliche elektronisch eingereichten Stimmen aus Basel-Stadt – darunter zahlreiche Auslandschweizerinnen und -schweizer – konnten nicht gezählt werden. Angesichts der klaren provisorischen Abstimmungsergebnisse schliessen die Behörden aus, dass sich die Mehrheitsentscheide dadurch verändert hätten. Politisch unverändert bleibt der Schaden dennoch erheblich: Stimmberechtigte wie die im Elsass wohnhafte Christine D'Souza kritisieren die späte Information und prüfen rechtliche Schritte wegen Verletzung ihrer politischen Rechte.
Der Regierungsrat von Basel-Stadt will die Ursachen des Vorfalls extern untersuchen lassen; die Staatsanwaltschaft hat wegen eines Anfangsverdachts auf ein Offizialdelikt ein Strafverfahren eröffnet. Parallel dazu hat der Kanton seine Teilnahme am E-Voting-Versuchsbetrieb bis zum 31. Dezember 2026 ausgesetzt, um Abläufe zu überprüfen und Korrekturmassnahmen zu erarbeiten. Die Bundeskanzlei begrüsst sowohl die externe Analyse als auch das strafrechtliche Vorgehen und betont, es müssten alle notwendigen Schritte unternommen werden, um eine Wiederholung zu verhindern.
Während Basel auf die Bremse tritt, halten andere Versuchskantone demonstrativ Kurs. Thurgau, Graubünden und St. Gallen erklärten in einer gemeinsamen Mitteilung, sie führten ihre Pilotprojekte mit dem E-Voting-System der Schweizerischen Post unverändert weiter. Das System habe sich seit 2023 in allen Wahlen und Abstimmungen bewährt, heisst es. Auch am 8. März sei der Einsatz in den beteiligten Gemeinden, darunter Amriswil und Bischofszell, problemlos verlaufen. Der Basler Vorfall habe nichts mit dem E-Voting-System als solchem zu tun, sondern sei auf die Handhabung einer externen Komponente, eben jenes USB-Sticks, zurückzuführen.
Bund und Kantone verweisen darauf, dass sich E-Voting weiterhin in einem bewusst eng gefassten Versuchsbetrieb befindet. Dieser sei darauf ausgelegt, technische und organisatorische Schwachstellen frühzeitig zu identifizieren und Prozesse laufend zu verbessern. Gleichwohl warnen Politologen vor einem möglichen Vertrauensverlust in der Bevölkerung: Die Basler Panne liefert Gegnern des elektronischen Abstimmens ein anschauliches Beispiel für Risiken und dürfte die politische Debatte um Tempo und Umfang des weiteren Ausbaus verschärfen – gerade in jenen Kantonen, die ihr digitales Angebot eigentlich ausweiten wollten.
